Stockreport

Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing [Yahoo! Finance]

Annexon, Inc. - common stock  (ANNX) 
PDF the 25th Annual Needham Healthcare Conference, describing 2026 as a “win year” after more than a decade of work developing therapies that target the classical complement [Read more]